Potent Treatment For Tuberculosis Found To Be Older Rarely-Used Antibiotic

Although Rifapentine is already approved for use in humans, it has no current market, not even a prescription price. Its makers stopped commercial production years ago, because demand was so low. But an antibiotic long abandoned as a weak, low-dose treatment for tuberculosis (TB) may have found renewed purpose, this time as a potent, high-dose fighter against the most common and actively contagious form of the lung disease. [click link for full article]

More: continued here

Filed under: Infectious Diseases / Bacteria / Viruses on December 20th, 2007